IDRX
Summary
IDRx is a clinical-stage biopharmaceutical company developing precision therapies to transform cancer care, focusing on highly potent and selective inhibitors like IDRX-42 and IDRX-73 that target key genetic drivers and drug-resistant mutations in gastrointestinal stromal tumors (GIST).
Deals Overview
Total Deals2
Valued Deals2
Total Value£ 194 M
Avg. Deal Size£ 97 M
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.
